Pharvaris (PHVS) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.67

Estimate

-$0.72

Surprise

+6.8%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Pharvaris (PHVS) reported a narrower loss than forecast — adjusted EPS of -$0.67 against the -$0.72 estimate (a 6.8% beat on a still-unprofitable quarter).

• Pharvaris Summarizes Clinical Data Presentations at ACAAI 2026 Annual Scientific Meeting — fiscal.ai, 2026-11-12
• Pharvaris Says 45% Of Patients On Oral Deucrictibant XR Were Attack-Free Over 24 Weeks In Phase 3 CHAPTER-3; No Treatmen — benzinga, 2026-11-12
• Pharvaris Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12

TrendMatrix currently rates PHVS Sell at 5.2/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +6.8% surprise compares with a -1.2% four-quarter average. Next scheduled report: 2027-04-01.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$33.36

Price target

$50.62

Stop

$31.02

Upside to target

+51.7%

Reward-to-risk

3.5:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.36B

P/E (fwd)

-11.1

52-week range

$23.01–$43.25

Off 52-week high

22.9%

RSI (14)

60

Volume vs avg

0.31×

Score today

5.2/10